Published in Virology on March 24, 2010
Effects of human immunodeficiency virus on the erythrocyte and megakaryocyte lineages. World J Virol (2013) 0.88
Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol (2003) 4.56
A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences. J Virol (2006) 2.05
Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis. Proc Natl Acad Sci U S A (2004) 1.72
Human immunodeficiency virus-associated autoimmune thrombocytopenic purpura: a review. Am J Med (1989) 1.68
HIV-1 coreceptor preference is distinct from target cell tropism: a dual-parameter nomenclature to define viral phenotypes. J Leukoc Biol (2006) 1.31
Human immunodeficiency virus inhibits multilineage hematopoiesis in vivo. J Virol (1998) 1.04
HIV-disease and bone marrow changes: a study of 60 cases. Eur J Haematol (1989) 1.03
Cytopenias in HIV infection: mechanisms and alleviation of hematopoietic inhibition. Curr HIV Res (2004) 1.03
Molecular determinants of the V3 loop of human immunodeficiency virus type 1 glycoprotein gp120 responsible for controlling cell tropism. J Gen Virol (1994) 0.97
Bone marrow examination in patients with AIDS and AIDS-related complex (ARC). Morphologic and in situ hybridization studies. Am J Clin Pathol (1989) 0.96
Ineffective platelet production in thrombocytopenic human immunodeficiency virus-infected patients. Blood (1998) 0.96
Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine. Blood (1991) 0.89
The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia. Br J Haematol (2000) 0.88
Pathophysiology of cardiopulmonary bypass: current issues. J Card Surg (1990) 0.86
Productive infection of CD34+-cell-derived megakaryocytes by X4 and R5 HIV-1 isolates. Virology (2000) 0.86
Potential use of human stem cell factor as adjunctive therapy for human immunodeficiency virus-related cytopenias. Blood (1991) 0.83
Impaired survival of bone marrow GPIIb/IIa+ megakaryocytic cells as an additional pathogenetic mechanism of HIV-1-related thrombocytopenia. Br J Haematol (1996) 0.83
Transcriptional regulation of megakaryopoiesis: thrombopoietin signaling and nuclear factors. Curr Opin Hematol (2006) 0.83
Distinct human immunodeficiency virus strains in the bone marrow are associated with the development of thrombocytopenia. J Virol (1999) 0.82
Co-receptor usage was more predictive than NSI/SI phenotype for HIV replication in macrophages: is NSI/SI phenotyping sufficient? J Leukoc Biol (2000) 0.81
Lack of compensatory megakaryocytopoiesis in HIV-1-seropositive thrombocytopenic individuals compared with immune thrombocytopenic purpura patients. AIDS (1991) 0.79
Serum thrombopoietin levels in thrombocytopenic and non-thrombocytopenic patients with human immunodeficiency virus (HIV-1) infection. Eur J Haematol (1999) 0.78
Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol (2008) 2.67
Bioluminescence imaging of myeloperoxidase activity in vivo. Nat Med (2009) 2.43
Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood (2009) 2.07
Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium. Leuk Lymphoma (2012) 1.48
The role of NF-{kappa}B-1 and NF-{kappa}B-2-mediated resistance to apoptosis in lymphomas. Proc Natl Acad Sci U S A (2006) 1.39
Human T-cell lymphotropic virus type 1 open reading frame II-encoded p30II is required for in vivo replication: evidence of in vivo reversion. J Virol (2004) 1.37
Induction of the Galpha(q) signaling cascade by the human immunodeficiency virus envelope is required for virus entry. J Virol (2008) 1.25
Foxp3 represses retroviral transcription by targeting both NF-kappaB and CREB pathways. PLoS Pathog (2006) 1.24
Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol (2002) 1.16
Animal models for human T-lymphotropic virus type 1 (HTLV-1) infection and transformation. Oncogene (2005) 1.15
Role of Abl kinase and the Wave2 signaling complex in HIV-1 entry at a post-hemifusion step. PLoS Pathog (2010) 1.14
Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood (2013) 1.13
HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition. Blood (2005) 1.09
Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants. Blood (2004) 1.09
Hsp40 facilitates nuclear import of the human immunodeficiency virus type 2 Vpx-mediated preintegration complex. J Virol (2007) 1.08
Identification of the nuclear localization signal of human immunodeficiency virus type 2 Vpx. Virology (2003) 1.07
IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma. Blood (2007) 1.06
Post-formulation peptide drug loading of nanostructures for metered control of NF-κB signaling. Biomaterials (2011) 1.04
Alpha interferon inhibits human T-cell leukemia virus type 1 assembly by preventing Gag interaction with rafts. J Virol (2003) 1.03
Human T-lymphotropic virus type-1 p30 alters cell cycle G2 regulation of T lymphocytes to enhance cell survival. Retrovirology (2007) 1.02
Analysis of HIV-2 Vpx by modeling and insertional mutagenesis. Virology (2006) 1.02
Human T-lymphotropic virus type 1 mitochondrion-localizing protein p13(II) is required for viral infectivity in vivo. J Virol (2006) 1.02
Cytolytic nanoparticles attenuate HIV-1 infectivity. Antivir Ther (2012) 1.02
Enhanced tumorigenesis in HTLV-1 tax-transgenic mice deficient in interferon-gamma. Blood (2004) 1.00
Integrase inhibitors effective against human T-cell leukemia virus type 1. Antimicrob Agents Chemother (2011) 0.97
Mechanisms of nanoparticle-mediated siRNA transfection by melittin-derived peptides. ACS Nano (2013) 0.95
Imaging spontaneous tumorigenesis: inflammation precedes development of peripheral NK tumors. Blood (2008) 0.95
Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047. J Clin Oncol (2012) 0.94
Acetylation of the human T-cell leukemia virus type 1 Tax oncoprotein by p300 promotes activation of the NF-kappaB pathway. Virology (2009) 0.94
Role of human immunodeficiency virus type 1 matrix phosphorylation in an early postentry step of virus replication. J Virol (2004) 0.94
Characterization of replication defects induced by mutations in the basic domain and C-terminus of HIV-1 matrix. Virology (2007) 0.94
The ARF tumor suppressor regulates bone remodeling and osteosarcoma development in mice. PLoS One (2010) 0.93
Vpx is critical for SIVmne infection of pigtail macaques. Retrovirology (2012) 0.93
T-cell activation promotes tumorigenesis in inflammation-associated cancer. Retrovirology (2009) 0.93
Molecular determinants of human T-lymphotropic virus type 1 transmission and spread. Viruses (2011) 0.92
Histone acetyltransferase (HAT) activity of p300 modulates human T lymphotropic virus type 1 p30II-mediated repression of LTR transcriptional activity. Virology (2006) 0.92
Structures of manganese polysulfides: mass-selected photodissociation and density functional calculations. Dalton Trans (2011) 0.90
Cholesterol dependence of HTLV-I infection. AIDS Res Hum Retroviruses (2005) 0.90
Human T-cell leukemia virus type 1 blunts signaling by interferon alpha. Virology (2008) 0.89
Engraftment and tumorigenesis of HTLV-1 transformed T cell lines in SCID/bg and NOD/SCID mice. Leuk Res (2002) 0.89
Chimeric SCID-hu Model as a Human Hematopoietic Stem Cell Host That Recapitulates the Effects of HIV-1 on Bone Marrow Progenitors in Infected Patients. J Stem Cells (2006) 0.88
Mutation of critical serine residues in HIV-1 matrix result in an envelope incorporation defect which can be rescued by truncation of the gp41 cytoplasmic tail. Virology (2008) 0.88
Photoelectron spectroscopy and density functional calculations of CuSi(n)- (n = 4-18) clusters. J Chem Phys (2012) 0.88
Molecular and clinical assessment in the treatment of AIDS Kaposi sarcoma with valproic Acid. Clin Infect Dis (2009) 0.87
Wip1 and p53 contribute to HTLV-1 Tax-induced tumorigenesis. Retrovirology (2012) 0.87
Biotherapeutic approaches to target cancer stem cells. J Stem Cells (2013) 0.86
Anti-Vpr activity of a yeast chaperone protein. J Virol (2004) 0.86
Hepatitis viruses and hepatocellular carcinoma in HIV-infected patients. Curr Opin Oncol (2002) 0.86
Identification of HIV-1 inhibitors targeting the nucleocapsid protein. J Med Chem (2012) 0.85
Rapid deep sequencing of patient-derived HIV with ion semiconductor technology. J Virol Methods (2013) 0.85
The HTLV-1 hbz antisense gene indirectly promotes tax expression via down-regulation of p30(II) mRNA. Virology (2010) 0.85
Modulation of beta-catenin and E-cadherin interaction by Vpu increases human immunodeficiency virus type 1 particle release. J Virol (2008) 0.84
Alpha interferon restricts human T-lymphotropic virus type 1 and 2 de novo infection through PKR activation. J Virol (2013) 0.84
Interaction of HIV-1 gag and membranes in a cell-free system. Virology (2002) 0.84
Sulfatide administration leads to inhibition of HIV-1 replication and enhanced hematopoeisis. J Stem Cells (2010) 0.83
Antiviral activity of a Rac GEF inhibitor characterized with a sensitive HIV/SIV fusion assay. Virology (2007) 0.83
Suppression of human T-cell leukemia virus I gene expression by pokeweed antiviral protein. J Biol Chem (2009) 0.82
Identification and characterization of 177 unreported genes associated with liver regeneration. Genomics Proteomics Bioinformatics (2004) 0.81
Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy (2014) 0.81
Association of primate T-cell lymphotropic virus infection of pig-tailed macaques with high mortality. Virology (2002) 0.81
Putative innate immunity of antiatherogenic paraoxanase-2 via STAT5 signal transduction in HIV-1 infection of hematopoietic TF-1 cells and in SCID-hu mice. J Stem Cells (2010) 0.81
Thrombocytopenia in HIV infection: impairment of platelet formation and loss correlates with increased c-Mpl and ligand thrombopoietin expression. Curr HIV Res (2006) 0.81
Potential yoga modules for treatment of hematopoietic inhibition in HIV-1 infection. J Stem Cells (2010) 0.80
HIV-2 viral protein X (Vpx) ubiquitination is dispensable for ubiquitin ligase interaction and effects on macrophage infection. Virology (2012) 0.80
Mechanical properties and failure mechanisms of graphene under a central load. Chemphyschem (2014) 0.80
Enhancement of cancer stem cell susceptibility to conventional treatments through complementary yoga therapy: possible cellular and molecular mechanisms. J Stem Cells (2012) 0.80
Therapeutic Application of Bone Marrow-Derived Stem Cells in a Patient with Methanol-Induced Blindness. J Stem Cells (2015) 0.79
HIV-2 Vpx protein interacts with interferon regulatory factor 5 (IRF5) and inhibits its function. J Biol Chem (2014) 0.79
In vivo analysis of replication and immunogenicity of proviral clones of human T-lymphotropic virus type 1 with selective envelope surface-unit mutations. Blood (2005) 0.79
Hematological malignancies: disease pathophysiology of leukemic stem cells. J Stem Cells (2013) 0.78
Substitution of HIV Type 1 Nef with HTLV-1 p12. AIDS Res Hum Retroviruses (2004) 0.78
Targeting HTLV-1 activation of NFκB in mouse models and ATLL patients. Viruses (2011) 0.78
The Smac mimetic RMT5265.2HCL induces apoptosis in EBV and HTLV-I associated lymphoma cells by inhibiting XIAP and promoting the mitochondrial release of cytochrome C and Smac. Leuk Res (2012) 0.78
Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019. Clin Lymphoma Myeloma (2006) 0.78
Antiaging Effects of an Intensive Mind and Body Therapeutic Program through Enhancement of Telomerase Activity and Adult Stem Cell Counts. J Stem Cells (2015) 0.77
Ayurveda for chemo-radiotherapy induced side effects in cancer patients. J Stem Cells (2013) 0.77
Rapid size dependent deletion of foreign gene sequences inserted into attenuated HIV-1 upon infection in vivo: implications for vaccine development. Curr HIV Res (2005) 0.76
Stem Cells in Aging: Influence of Ontogenic, Genetic and Environmental Factors. J Stem Cells (2006) 0.75
Conference highlights of the 16th International Conference on Human Retrovirology: HTLV and related retroviruses, 26-30 June 2013, Montreal, Canada. Retrovirology (2014) 0.75
Tunable thermal transport and mechanical properties of graphyne heterojunctions. Phys Chem Chem Phys (2016) 0.75
Induction characterization and targeting of human hematopoietic cancer stem cells. J Stem Cells (2010) 0.75
Erratum: Structural isomerism in gold nanoparticles revealed by X-ray crystallography. Nat Commun (2015) 0.75
Large scale of identification of differentially expressed genes in the regenerating rat liver after SISPH. Sci China C Life Sci (2005) 0.75
Sulfatide--a new candidate for ART treatment in HIV-1 infection. J Stem Cells (2012) 0.75
Development and validation of a need-based integrated yoga program for cancer patients: a retrospective study. J Stem Cells (2012) 0.75
Reversal of Methanol-Induced Blindness in Adults by Autologous Bone Marrow-Derived Stem Cells: A Case Series. J Stem Cells (2015) 0.75
Rescue of multi-lineage hematopoiesis during HIV-1 infection by human c-mpl gene transfer and reconstitution of CD34+ progenitor cells in vivo. J Stem Cells (2009) 0.75
Biomarker discovery and biotherapeutics applications of photosynthetic light-harvesting and bioluminescence light-emitting chromophore-protein complexes in stem cell biology and regenerative medicine. J Stem Cells (2014) 0.75
Degeneration versus Regeneration. J Stem Cells (2015) 0.75